Abstract

Most cancer chemotherapy protocols in current use have been established empirically, and combination therapies have generally been designed based on single-agent activity and nonoverlapping toxicities. However, advances in our understanding of the molecular pathophysiology of human cancers indicate

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call